Radiopharma Telix reorganizes leadership

Radiopharmaceuticals company  Telix Pharmaceuticals Ltd. (ASX:TLX) announced three leadership changes, naming Richard Valeix CEO of Telix Therapeutics, Kevin Richardson CEO of Telix Precision Medicine and Raphael Ortiz CEO of Telix International. Valeix was group CCO; Richardson was CEO, Americas; and Ortiz was CEO, EMEA and APAC. Telix said the changes were part of a restructuring to optimize the development and commercialization of theranostic radiopharmaceuticals by organizing the company around the four business units of therapeutics, diagnostics, medtech and manufacturing. 

President and CEO Blaise Coleman will depart Endo Inc. (OTCQX:NDOI) on Aug. 29. Scott Hirsch, a member of Endo’s board, will become interim CEO, while the specialty pharma searches for a successor. ...